PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Publication Type:

Journal Article

Source:

Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 17, Issue 8, p.2400-9 (2011)

Keywords:

2011, Adult, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Center-Authored Paper, Chemotherapy, Adjuvant, Clinical Research Division, Doxorubicin, Female, Fluorodeoxyglucose F18, Humans, Kinetics, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Outcome Assessment (Health Care), Positron-Emission Tomography, Prognosis, Proportional Hazards Models, Radiopharmaceuticals, Reproducibility of Results, Research Trials Office Core Facility - Biostatistics Service, Sensitivity and Specificity, Shared Resources, Survival Analysis

Abstract:

Changes in tumor metabolism from positron emission tomography (PET) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are predictive of pathologic response. Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS).